Skip to main content
Top
Published in: Journal of General Internal Medicine 2/2020

01-02-2020 | Hypertension | Clinical Practice: Clinical Vignettes

Unexplained Symptomatic Paroxysmal Hypertension: a Diagnostic and Management Challenge

Authors: Kelly Dyer, MD, Theresa E. Vettese, MD

Published in: Journal of General Internal Medicine | Issue 2/2020

Login to get access

Excerpt

Symptomatic paroxysmal hypertension is considered the hallmark symptom of pheochromocytomas. Pheochromocytomas, however, are exceedingly rare and are diagnosed in 2% of patients with hypertensive paroxysms.1 As a result, clinicians and patients are often left frustrated and confused when a diagnostic evaluation of symptomatic paroxysmal hypertension is un-revealing for a pheochromocytoma. Frequently, these patients undergo multiple and often unnecessary testing, as was the case with our patient. The differential diagnosis is broader than most clinicians realize and includes conditions such as prescription and illicit drug use, obstructive sleep apnea, panic attacks, and pseudopheochromocytoma. Of these, pseudopheochromocytoma is perhaps the least understood and considered. …
Literature
1.
go back to reference Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134 (4):315-329.CrossRef Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134 (4):315-329.CrossRef
2.
go back to reference Kuchel O, Buu NT, Hamet P, Larochelle P, Bourque M, Genest J. Essential hypertension with low conjugated catecholamines imitates pheochromocytoma. Hypertension. 1981;3(3) :347-355.CrossRef Kuchel O, Buu NT, Hamet P, Larochelle P, Bourque M, Genest J. Essential hypertension with low conjugated catecholamines imitates pheochromocytoma. Hypertension. 1981;3(3) :347-355.CrossRef
3.
go back to reference Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF, Holmes C, Pacak K, Eisenhofer G. Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens. 2007;25(11):2286-2295.CrossRef Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF, Holmes C, Pacak K, Eisenhofer G. Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens. 2007;25(11):2286-2295.CrossRef
4.
go back to reference Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma): Understanding the cause and treatment. Arch Intern Med. 1999;159 (7):670-674.CrossRef Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma): Understanding the cause and treatment. Arch Intern Med. 1999;159 (7):670-674.CrossRef
5.
go back to reference Mann SJ. Severe paroxysmal hypertension: An automatic syndrome and its relationship to repressed emotions. Psychosomatics. 1996;37(5):444-450.CrossRef Mann SJ. Severe paroxysmal hypertension: An automatic syndrome and its relationship to repressed emotions. Psychosomatics. 1996;37(5):444-450.CrossRef
6.
go back to reference Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma). Curr Hypertens Rep. 2008;10 (1):12-18.CrossRef Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma). Curr Hypertens Rep. 2008;10 (1):12-18.CrossRef
7.
go back to reference Mackenzie IS, Brown JB. Pseudopheochromoctyoma. J Hypertens. 2007;(24):2204-2206.CrossRef Mackenzie IS, Brown JB. Pseudopheochromoctyoma. J Hypertens. 2007;(24):2204-2206.CrossRef
8.
go back to reference Hamada M, Shigematsu Y, Mukai M, Kazatani Y, Kokubu T, Hiwada K. Blood pressure response to the Valsalva maneuver in pheochromocytoma and pseudopheochromocytoma. Hypertension. 1995;25(2):266-271.CrossRef Hamada M, Shigematsu Y, Mukai M, Kazatani Y, Kokubu T, Hiwada K. Blood pressure response to the Valsalva maneuver in pheochromocytoma and pseudopheochromocytoma. Hypertension. 1995;25(2):266-271.CrossRef
9.
go back to reference Kuchel O, Buu NT, Hamet P, Larochelle P, Bourque M, Genest J. Dopamine surges in hyperadrenergic essential hypertension. Hypertension. 1982;4(6):845-852.CrossRef Kuchel O, Buu NT, Hamet P, Larochelle P, Bourque M, Genest J. Dopamine surges in hyperadrenergic essential hypertension. Hypertension. 1982;4(6):845-852.CrossRef
10.
go back to reference Pickering T, Clemow L. Paroxysmal hypertension: The role of stress and psychological factors. J Clin Hypertens. 2008; 10 (7): 575-581.CrossRef Pickering T, Clemow L. Paroxysmal hypertension: The role of stress and psychological factors. J Clin Hypertens. 2008; 10 (7): 575-581.CrossRef
11.
go back to reference Eisenhofer G, Sharabi Y, Pacak K. Unexplained symptomatic paroxysmal hypertension in pseudopheochromocytoma: A stress response disorder? Ann N Y Acad Sci. 2008; 1148: 469-478.CrossRef Eisenhofer G, Sharabi Y, Pacak K. Unexplained symptomatic paroxysmal hypertension in pseudopheochromocytoma: A stress response disorder? Ann N Y Acad Sci. 2008; 1148: 469-478.CrossRef
12.
go back to reference Dobri G., Bravo E., Hamrachian A. Pheochromocytoma: Pitfalls in the biochemical evaluation. Expert Rev Endocrinol Metab. 2014; 9 (2): 123-135.CrossRef Dobri G., Bravo E., Hamrachian A. Pheochromocytoma: Pitfalls in the biochemical evaluation. Expert Rev Endocrinol Metab. 2014; 9 (2): 123-135.CrossRef
13.
go back to reference Martucci VL, Pacak K. Pheochromocytoma and Paraganglioma: diagnosis, genetics, management and treatment, Curr Probl Cancer. 2014; 38(1): 7-41.CrossRef Martucci VL, Pacak K. Pheochromocytoma and Paraganglioma: diagnosis, genetics, management and treatment, Curr Probl Cancer. 2014; 38(1): 7-41.CrossRef
14.
go back to reference Mann SJ. Labile and Paroxysmal Hypertension: Common Clinical Dilemmas in Need of Treatment Studies. Curr Cardiol Rep. 2015;17(11):99.CrossRef Mann SJ. Labile and Paroxysmal Hypertension: Common Clinical Dilemmas in Need of Treatment Studies. Curr Cardiol Rep. 2015;17(11):99.CrossRef
15.
go back to reference Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017;11(1):54-65.CrossRef Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017;11(1):54-65.CrossRef
16.
go back to reference Mann SJ. Neurogenic hypertension: Pathophysiology, diagnosis and management. Clin Auton Res. 2018; 28: 363-374.CrossRef Mann SJ. Neurogenic hypertension: Pathophysiology, diagnosis and management. Clin Auton Res. 2018; 28: 363-374.CrossRef
17.
go back to reference Vaclavik J, Krenkova E, Vaclavik T, Kamasova M. Effect of sertraline in paroxysmal hypertension. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018; 162 (2): 116-120.CrossRef Vaclavik J, Krenkova E, Vaclavik T, Kamasova M. Effect of sertraline in paroxysmal hypertension. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018; 162 (2): 116-120.CrossRef
Metadata
Title
Unexplained Symptomatic Paroxysmal Hypertension: a Diagnostic and Management Challenge
Authors
Kelly Dyer, MD
Theresa E. Vettese, MD
Publication date
01-02-2020
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 2/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05503-8

Other articles of this Issue 2/2020

Journal of General Internal Medicine 2/2020 Go to the issue